Scientists Re-Analyze old samples to unlock secrets of HER2-Low breast cancer
NCT ID NCT07561346
First seen May 03, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study looked at tissue samples from 2751 women with early breast cancer who had already been treated with chemotherapy. The goal was to see if cancers with low levels of HER2 protein (HER2-low) are different from those with no HER2 (HER2-zero). By comparing these groups, researchers hope to better understand the disease and guide future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 LOW AND HER2 ZERO PATIENTS WITH OPERABLE BREAST CANCER TREATED WITH DDS-CT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hellenic Cooperative Oncology Group (HeCOG)
Athens, 11526, Greece
Conditions
Explore the condition pages connected to this study.